Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
Iihara H, Shimokawa M, Hayasaki Y, Fujita Y, Abe M, Takenaka M, Yamamoto S, Arai T, Sakurai M, Mori M, Nakamura K, Kado N, Murase S, Shimaoka R, Suzuki A, Morishige KI. Iihara H, et al. Among authors: hayasaki y. Gynecol Oncol. 2020 Mar;156(3):629-635. doi: 10.1016/j.ygyno.2020.01.004. Epub 2020 Jan 9. Gynecol Oncol. 2020. PMID: 31926638 Free article. Clinical Trial.
Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials.
Yamamoto S, Iihara H, Uozumi R, Kawazoe H, Tanaka K, Fujita Y, Abe M, Imai H, Karayama M, Hayasaki Y, Hirose C, Suda T, Nakamura K, Suzuki A, Ohno Y, Morishige KI, Inui N. Yamamoto S, et al. Among authors: hayasaki y. BMC Cancer. 2021 Jul 19;21(1):832. doi: 10.1186/s12885-021-08572-3. BMC Cancer. 2021. PMID: 34281514 Free PMC article. Clinical Trial.
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.
Yamamoto S, Iihara H, Uozumi R, Kawazoe H, Tanaka K, Fujita Y, Abe M, Imai H, Karayama M, Hayasaki Y, Hirose C, Suda T, Nakamura K, Suzuki A, Ohno Y, Morishige KI, Inui N. Yamamoto S, et al. Among authors: hayasaki y. BMC Cancer. 2022 Mar 23;22(1):310. doi: 10.1186/s12885-022-09392-9. BMC Cancer. 2022. PMID: 35321690 Free PMC article. Clinical Trial.
Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.
Iihara H, Shimokawa M, Abe M, Hayasaki Y, Fujita Y, Nagasawa Y, Sakurai M, Matsuoka R, Suzuki A, Morishige K. Iihara H, et al. Among authors: hayasaki y. BMJ Open. 2019 Jan 17;9(1):e024357. doi: 10.1136/bmjopen-2018-024357. BMJ Open. 2019. PMID: 30782732 Free PMC article.
[Clinical efficacy of cefpirome sulfate against Bacteroides species, Prevotella species and Porphyromonas species. Society of Anaerobic Bacterial Infections in the fields of obstetrics and gynecology in Gifu].
Mikamo H, Sato Y, Hayasaki Y, Hua YX, Tamaya T, Iwasa S, Kawazoe K, Furuta N, Ito M, Nomura M, Tsukahara Y, Furui K, Sakakibara K, Hattori S, Sugiyama M, Ohnishi N, Hirose R, Nakagawa M, Yamada Y, Hashiyama T, Arahori K, Izumi K, Shiraki S, Morishita S, Watanabe K. Mikamo H, et al. Among authors: hayasaki y. Jpn J Antibiot. 2000 Jan;53(1):26-45. Jpn J Antibiot. 2000. PMID: 10709144 Clinical Trial. Japanese.
116 results